



## Grünenthal GmbH

EUR 400,000,000 3.625% Senior Secured Notes due 2026

XS2337064856 and XS2337065077

EUR 550,000,000 4.125% Senior Secured Notes due 2028

XS2337703537 and XS2337703610

EUR 300,000,000 6.750% Senior Secured Notes due 2030

XS2615562274 and XS2615563082

### Grünenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration

**Aachen, Germany and Tokyo, Japan, 2 August 2023** – Grünenthal GmbH (CEO: Gabriel Baertschi), a global, science-based, privately-owned pharmaceutical company and Kyowa Kirin Co., Ltd., (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the successful completion of a deal to enter into a Joint Venture Collaboration for Kyowa Kirin International's established medicines portfolio.

The portfolio comprises 13 brands across six therapeutic areas primarily focused on pain management, including Abstral® and PecFent® for breakthrough cancer pain, Moventig® for opioid-induced constipation, and Adcal-D3® for osteoporosis. All products will continue to be marketed through affiliates in seven major European countries and through a network of partners in various additional territories worldwide.

Grünenthal owns a 51 percent majority share in the Joint Venture Collaboration, while Kyowa Kirin owns a 49 percent share. Grünenthal intends to fully acquire the remaining 49 percent share via exercising an option at the beginning of 2026.

**For further information, please refer to the just published press release or contact:**

**Anna Carduck**  
Creditor Relations

Phone: +49 241 569 3767  
[creditor-relations@grunenthal.com](mailto:creditor-relations@grunenthal.com)

Grünenthal GmbH  
52099 Aachen | Germany  
[www.grunenthal.com](http://www.grunenthal.com)